Brian Kushner
Memorial Sloan Kettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Brian Kushner as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:18 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06528496 · N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With NeuroblastomaMemorial Sloan Kettering Cancer Center · recruiting · High-risk Neuroblastoma, Neuroblastoma, Childhood Neuroblastoma · principal investigator
- Ph2NCT06057948 · A Study of a Vaccine in Combination With Beta-glucan in People With NeuroblastomaMemorial Sloan Kettering Cancer Center · recruiting · Neuroblastoma, High-risk Neuroblastoma, Metastatic Neuroblastoma · principal investigator
- Early Ph1NCT04947501 · A Study of N9 Chemotherapy in Children With NeuroblastomaMemorial Sloan Kettering Cancer Center · active not recruiting · Neuroblastoma, Pediatric Cancer · principal investigator
- Ph2NCT04936529 · A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With NeuroblastomaMemorial Sloan Kettering Cancer Center · recruiting · Neuroblastoma · principal investigator
- N/ANCT04501757 · Naxitamab and GM-CSF in People With NeuroblastomaMemorial Sloan Kettering Cancer Center · no longer available · High-Risk Neuroblastoma · principal investigator
- N/ANCT02100930 · Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk NeuroblastomaMemorial Sloan Kettering Cancer Center · completed · Neuroblastoma · principal investigator
- Ph1/Ph2NCT01757626 · Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk NeuroblastomaMemorial Sloan Kettering Cancer Center · active not recruiting · Neuroblastoma · principal investigator
- Ph2NCT01183897 · 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone MarrowMemorial Sloan Kettering Cancer Center · completed · Neuroblastoma · principal investigator
- Ph2NCT01183884 · 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk NeuroblastomaMemorial Sloan Kettering Cancer Center · terminated · Neuroblastoma · principal investigator
- Ph2NCT01183416 · High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell TransplantationMemorial Sloan Kettering Cancer Center · completed · Neuroblastoma · principal investigator
- Ph2NCT01183429 · 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk NeuroblastomaMemorial Sloan Kettering Cancer Center · completed · Neuroblastoma · principal investigator
- Ph1/Ph2NCT00911560 · Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk NeuroblastomaMemorial Sloan Kettering Cancer Center · completed · Neuroblastoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:18 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in neuroblastoma, ranked by citations from NIH iCite, fetched 2026-11-12 11:18 UTC. The ranking covers the 200 most relevant of 35 PubMed records, and a shared surname and initials can bring in a namesake. All 35 on PubMed
- 214 citationsRCR 5.6
- Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma.J Clin Oncol · 2001161 citationsRCR 3.3
- Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age.J Clin Oncol · 1998153 citationsRCR 3.6
- 115 citationsRCR 3.1
- 111 citationsRCR 3.7
- Phase I trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission.Clin Cancer Res · 2014109 citationsRCR 3.1
- Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma.J Clin Oncol · 2004107 citationsRCR 2.6
- Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery.J Clin Oncol · 200197 citationsRCR 2.2
- N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age.Med Pediatr Oncol · 200196 citationsRCR 2.4
- Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression.J Clin Oncol · 202194 citationsRCR 5.1